- Founded: 2011
- Headquarters: Brisbane, CA
- aimmune.com
- pipeline: http://www.aimmune.com/pipeline
food allergies focused biotech co surging higher following DBVT news (DBVT missed primary endpoint in Phase 3 trial)
Monday, October 23, 2017
=Aimmune Therapeutics (AIMT) : surging higher following DBVT news
Aimmune is developing treatments for life-threatening food allergies; lead product AR101 is in Phase III for peanut allergy with US FDA Breakthrough Therapy Designation
food allergies focused biotech co surging higher following DBVT news (DBVT missed primary endpoint in Phase 3 trial)
food allergies focused biotech co surging higher following DBVT news (DBVT missed primary endpoint in Phase 3 trial)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment